Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Compounds</td><td class="align_center">Model</td><td class="align_center">EMT-related target</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">IL-37 [<a href="/journals/crj/2023/3291957/#B77" target="_blank">77</a>]</td><td class="align_center">House dust mite-induced asthmatic mice</td><td class="align_center">Erk1/2 and STAT3</td></tr><tr><td class="align_left">Carbocisteine [<a href="/journals/crj/2023/3291957/#B78" target="_blank">78</a>]</td><td class="align_center">OVA-induced asthmatic mice</td><td class="align_center">TGF-<i>β</i>1</td></tr><tr><td class="align_left">The recombinant pyrin domain protein [<a href="/journals/crj/2023/3291957/#B79" target="_blank">79</a>]</td><td class="align_center">Asthmatic mice</td><td class="align_center">TGF-<i>β</i>1/Smad and Jagged1/Notch1</td></tr><tr><td class="align_left">Empagliflozin [<a href="/journals/crj/2023/3291957/#B80" target="_blank">80</a>]</td><td class="align_center">Asthmatic mice</td><td class="align_center">Autophagy</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Specific cytokines or amino acids involved in EMT in different respiratory symptoms.</div>

Canadian Respiratory Journal

tab3

Table 3

Table 3: Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression 